Atossa

Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

Retrieved on: 
火曜日, 5月 28, 2024
Biostatistics, Tobacco, CEM, Risk, SMART, Mammography, Clinical trial, Therapy, Breast cancer, Karolinska Institute, AI, Cancer, Hormone replacement therapy, Medicine, Body mass index, Woman, Artificial intelligence, Breast, Risk assessment, History, Principal, Atossa, Medical imaging

SEATTLE, May 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced support for a new Phase 2 study designed to validate an innovative, artificial intelligence driven, breast cancer risk assessment model.

Key Points: 
  • SEATTLE, May 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced support for a new Phase 2 study designed to validate an innovative, artificial intelligence driven, breast cancer risk assessment model.
  • Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
  • Mammogram results and additional assessment data will be analyzed by a proprietary algorithm known as the Profound Artificial Intelligence (AI) Risk Assessment Model (“Profound AI Model”), which will determine each participant’s risk of developing breast cancer in the next two years.
  • These are factors that are currently not included in the widely used Breast Cancer Risk Assessment Tool (BCRAT), also known as The Gail Model.

Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial

Retrieved on: 
水曜日, 5月 15, 2024
Breast, Mammography, Woman, Therapy, Breast cancer, Neoplasm, Cancer, Incidence, MBD, Atossa, Pharmaceutical industry

SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the last patient in the Company’s Karisma-Endoxifen clinical trial received their final dose of study medication.

Key Points: 
  • SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the last patient in the Company’s Karisma-Endoxifen clinical trial received their final dose of study medication.
  • Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
  • The Karisma-Endoxifen study, which fully enrolled in November 2023, is a 240-person Phase 2 clinical trial investigating (Z)-endoxifen in premenopausal women with measurable mammographic breast density (MBD).
  • Medication-induced MBD reduction has been associated with a 50% to 63% reduction in the incidence of breast cancer in a three-to-fifteen-year follow-up period.

Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines

Retrieved on: 
火曜日, 5月 7, 2024
Mortality, Breast, Woman, USPSTF, U.S. FDA, Atossa, Patient, Breast cancer screening, Diagnosis, Health, Therapy, Breast cancer, Medical imaging

SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced its support of new guidelines released by the U.S. Preventive Services Task Force (USPSTF) recommending that women begin breast cancer screening starting at age 40.

Key Points: 
  • SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced its support of new guidelines released by the U.S. Preventive Services Task Force (USPSTF) recommending that women begin breast cancer screening starting at age 40.
  • Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
  • The change to the recommended age comes in response to rising breast cancer rates among younger women and racial disparities in breast cancer diagnosis and mortality.
  • Atossa Therapeutics recognizes the significance of these improved guidelines in empowering both healthcare providers and patients to make informed decisions regarding breast cancer screening and treatment.

Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

Retrieved on: 
月曜日, 4月 15, 2024
CDK, University, Learning, Risk, Woman, Quantum Leap, Eli Lilly, Recurrence, Atossa, Patient, EOP, MRI, Neoplasm, Eli Lilly and Company, AACR, Therapy, Breast cancer, Pharmaceutical industry

Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

Key Points: 
  • Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
  • The new study arm will enroll approximately 20 women with newly diagnosed Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) invasive breast cancer.
  • Participants will receive 40mg (Z)-endoxifen once daily in combination with 150mg abemaciclib twice daily for a total of 24 weeks prior to surgery.
  • “Women with high clinical stage but less proliferative tumors (molecularly low risk or those with late recurrence risk) are challenging to treat.

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

Retrieved on: 
木曜日, 4月 11, 2024
Noble, Atossa, Therapy, Conference, Breast cancer

SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that Chief Executive Officer Steven Quay, M.D., Ph.D., will speak at the Noble Capital Markets Emerging Growth Healthcare Conference on Wednesday, April 17 at 9:00 am ET.

Key Points: 
  • SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that Chief Executive Officer Steven Quay, M.D., Ph.D., will speak at the Noble Capital Markets Emerging Growth Healthcare Conference on Wednesday, April 17 at 9:00 am ET.
  • The presentation will be available virtually and members of the Company’s leadership team will be available for one-on-one meetings with registered investors of the conference.
  • Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
  • Individuals interested in viewing the live presentation can register for the free event here: Noble Healthcare Conference Registration .

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

Retrieved on: 
火曜日, 4月 9, 2024
Plasma, MRI, Neoplasm, Atossa, Ki-67, Associate, RECIST, Magnetic resonance imaging, Incidence, Patient, MD, Woman, AACR, Clinical trial, Therapy, Breast cancer, Safety, Division, Recurrence, Exemestane, Annual general meeting, Medical imaging

SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and efficacy data from the Company’s Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial.

Key Points: 
  • SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and efficacy data from the Company’s Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial.
  • Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
  • The data, which is being presented at the American Association for Cancer Research (AACR) Annual Meeting, is from the 40mg pharmacokinetic (PK) run-in cohort of the study.
  • At 28 days, six of the seven had Ki-67 levels below 10% and stayed on treatment for an additional five months.

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
月曜日, 4月 1, 2024
Comparison, Atossa, Patient, Mayo Clinic, Neoplasm, Ductal carcinoma, Woman, AACR, CFA, Clinical trial, Therapy, Breast cancer, Safety, DCIS, FDA, Exemestane, Breast, Annual general meeting, Pharmaceutical industry

SEATTLE, April 01, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on recent Company developments.

Key Points: 
  • SEATTLE, April 01, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on recent Company developments.
  • Full enrollment was achieved in November 2023 and data is expected in the second half of 2024.
  • Factors contributing to the increased operating expenses in the year ended December 31, 2023 are explained below.
  • The following table provides a breakdown of major categories within R&D expense for the years ended December 31, 2023 and 2022, together with the dollar change in those categories (in thousands):

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

Retrieved on: 
月曜日, 3月 18, 2024
Atossa, Breast cancer, Therapy

SEATTLE, March 18, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that on March 15, 2024, the Company received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2).

Key Points: 
  • SEATTLE, March 18, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that on March 15, 2024, the Company received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2).
  • Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology, with a focus on using (Z)-endoxifen to prevent and treat breast cancer.
  • As previously disclosed, on September 26, 2023, the Company was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days.
  • To regain compliance, the Company was required to maintain a minimum closing bid price of $1.00 per share for at least 10 consecutive trading days.

Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors

Retrieved on: 
火曜日, 3月 12, 2024
Harvard College, Health, Internal medicine, Public health, Disease, Atossa, Oncology, Patient, Cornell University, Weill Cornell Medical Center, Woman, Helsinki University Central Hospital, Clinical trial, Therapy, Breast cancer, Hematology, Weill Cornell Medicine, Pharmaceutical industry

Dr. Cigler is a medical oncologist and clinical investigator at the Weill Cornell Breast Center in New York City.

Key Points: 
  • Dr. Cigler is a medical oncologist and clinical investigator at the Weill Cornell Breast Center in New York City.
  • “We are pleased to welcome Dr. Cigler to our board of directors,” said Steven Quay, M.D., Ph.D., Atossa’s President and Chief Executive Officer.
  • “Tessa works daily with breast cancer patients and knows firsthand the critical need for more effective and tolerable treatment options.
  • While progress has been made over the past decade, breast cancer remains a deadly disease for hundreds of thousands of women globally each year.

Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
水曜日, 3月 6, 2024
Breast cancer, Cancer, Woman, Neoadjuvant therapy, Atossa, AACR, Exemestane, Therapy, Health, Patient, Estrogen receptor

The EVANGELINE study is investigating (Z)-endoxifen as a neoadjuvant treatment for premenopausal women diagnosed with Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer.

Key Points: 
  • The EVANGELINE study is investigating (Z)-endoxifen as a neoadjuvant treatment for premenopausal women diagnosed with Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer.
  • Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology, with a focus on breast cancer.
  • “We're excited that the EVANGELINE data from the 40 mg cohort of patients was accepted for presentation at the 2024 American Association for Cancer Research Annual Meeting,” said Dr. Steven Quay, Atossa’s President and Chief Executive Officer.
  • Organized by the American Association for Cancer Research, the AACR Annual Meeting is the largest and most important cancer drug discovery event in the world.